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Abstract
IMPORTANCE Elevated lipoprotein(a) (Lp[a]) levels are associated with atherosclerotic
cardiovascular diseases. The association between high Lp(a) levels and human longevity phenotypes
is, however, controversial.
OBJECTIVE To examine whether genetically determined Lp(a) levels are associated with parental
life span and chronic disease–free survival (health span) and the association between Lp(a) levels and
long-term, all-cause mortality risk.
DESIGN, SETTING, ANDPARTICIPANTS In this genetic association study, cross-sectional
mendelian randomization (UK Biobank [2006-2010] and LifeGen Consortium) and prospective
analyses (European Prospective Investigation Into Cancer and Nutrition (EPIC)-Norfolk [1993-1997,
with patients followed up to 2016]) were conducted using individual-level data on 139 362
participants. The association between a weighted genetic risk score of 26 independent single-
nucleotide polymorphisms at the LPA locus on parental life span using individual participant data
from the UK Biobank, as well as with summary statistics of a genome-wide association study of more
than 1 million life spans (UK Biobank and LifeGen), were examined. The association between these
single-nucleotide polymorphisms and the age at the end of the health span was tested using
summary statistics of a previous genome-wide association study in the UK Biobank. The association
between Lp(a) levels and all-cause mortality in the EPIC-Norfolk study was also investigated. Data
were analyzed fromDecember 2018 to December 2019.
EXPOSURES Genetically determined andmeasured Lp(a) levels.
MAINOUTCOMES ANDMEASURES Parental life span, health span, and all-causemortality.
RESULTS In 139 362 white British participants (mean [SD] age, 62.8 [3.9] years; 52%women) from
theUKBiobank, increases in the genetic risk score (weighted for a 50-mg/dL increase in Lp[a] levels)
were inversely associated with a high parental life span (odds ratio, 0.92; 95% CI, 0.89-0.94;
P = 2.7 × 10−8). Using the Egger-mendelian randomizationmethod, a negative association between
LPA single-nucleotide polymorphisms and parental life span (mean [SD] Egger-mendelian
randomization slope, −0.0019 [0.0002]; P = 2.22 × 10−18) and health span (−0.0019 [0.0003];
P = 3.00 × 10−13) was noted. In 18 720 participants from EPIC-Norfolk (5686 cases), the mortality
risk for those with Lp(a) levels equal to or above the 95th percentile was equivalent to being 1.5 years
older in chronologic age (β coefficient [SE], 0.194 [0.064]).
(continued)
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE The results of this study suggest a potential causal effect of
absolute Lp(a) levels on human longevity as defined by parental life span, health span, and all-cause
mortality. The results also provide a rationale for trials of Lp(a)-lowering therapy in individuals with
high Lp(a) levels.
JAMA Network Open. 2020;3(2):e200129. doi:10.1001/jamanetworkopen.2020.0129
Introduction
Lipoprotein(a) (Lp[a]) consists of a low-density lipoprotein attached to apolipoprotein(a) by a
disulfide bond. Plasma levels of Lp(a) are associated with a higher risk of a broad range of
atherosclerotic cardiovascular disease (CVD).1-5 The evidence linking Lp(a) levels and Lp(a)-raising
genetic variants with all-cause mortality is not as consistent. A 1998 study of healthy centenarian
individuals initiated a debate about the potential association between Lp(a) and longevity following
the report that up to one-quarter of that population had high Lp(a) levels in the absence of any
atherosclerotic CVD.6 Another study of patients with documented coronary heart disease found no
evidence of an association between high Lp(a) levels and all-cause mortality.7 A recently published
study by Langsted et al8 revealed an association between high Lp(a) levels and cardiovascular and
all-cause mortality in the general Danish population. This association could be owing to the fact that
individuals with high Lp(a) levels are typically characterized by a smaller apolipoprotein(a)
isoform size.
Whether high Lp(a) levels predict human longevity phenotypes is an issue of particular
relevance as Lp(a)-lowering therapies are currently being developed; one of them (an antisense
oligonucleotide against LPA called AKCEA-APO[a]-Lrx)
9 is expected to be tested in a planned large,
phase 3 cardiovascular outcomes trial. Determining the association between high Lp(a) levels in
large, prospective studies would provide information on the potential of these therapies to extend
the life span in individuals with high Lp(a) levels.
The definition of what constitutes longevity in human genetic studies is highly debated, and the
lack of a universally recognized definition increases the possibility of biases, hindering external
validation efforts, especially for case-control studies.10 Results of many studies on centenarian or
other long-lived individuals might have been confounded by the use of different birth cohorts of
centenarians and controls, selection bias, or survival bias. Parental life span is a novel and innovative
tool that is increasingly used to study the genetic makeup of human longevity that considerably
reduces selection bias as both cases and controls are uniformly recruited. Two genome-wide
association studies identified variants at the LPA locus to be associated with shorter life span as
estimated by parental life span.11,12
Although studying the genetic determinants of life span is necessary to improve our
understanding of the complexity of human longevity, addressing the global challenges of aging is
equally important to improve the quality of care of aging individuals. The association between
measured and genetically determined Lp(a) levels and human longevity is controversial and, despite
evidence suggesting that LPAmight be a locus influencing longevity, it is unknownwhether a
concentration-dependent effect of Lp(a) levels on human longevity exists. In this study, we used a
2-sample mendelian randomization (MR) design to determine whether genetic variants associated
with elevated Lp(a) levels are associatedwith human longevity phenotypes, as estimated by parental
life span and the age at the end of the chronic disease–free survival (health span), in the UK Biobank.
We also investigated the association betweenmeasured and genetically determined Lp(a) levels and
long-term all-cause and cardiovascular mortality in another cohort from the United Kingdom: the
European Prospective Investigation Into Cancer and Nutrition (EPIC)-Norfolk study.
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Methods
Study Populations
We used a 2-sample cross-sectional MR study design to assess the relationship between genetically
predicted Lp(a) levels and longevity phenotypes. eFigure 1 in the Supplement presents further details
on the design of the study and a description of how exposures and outcomes were defined. The
association between LPA variants and parental life span and the age at the end of the health spanwas
assessed in the UK Biobank. Our MR analysis included 139 362 white individuals between ages 55
and 69 years recruited between 2006 and 2010 in several centers in the United Kingdom (eMethods
1 in the Supplement).13 Data analysis was conducted between December 2018 and December 2019.
The association between genetically determined and measured Lp(a) levels and long-term all-cause
and cardiovascular mortality was assessed in the EPIC-Norfolk study, which is a population-based
study of 25 663men and women aged 45 to 79 years residing in Norfolk, United Kingdom.
Participants were recruited bymail from age-sex registers of general practices in Norfolk. The design,
methods of the study, and baseline characteristics of the study participants have been described
previously.4,14 At the baseline survey conducted between 1993 and 1997 (with patients followed up
to 2016), participants completed a detailed health and lifestyle questionnaire. Lipoprotein(a) levels
were measured with an immune-turbidimetric assay using polyclonal antibodies directed against
epitopes in apolipoprotein(a) (Denka Seiken), as previously described.15 The distribution of Lp(a) in
participants of EPIC-Norfolk is presented in eFigure 2 in the Supplement. The Norwich District Health
Authority Ethics Committee approved the study, and all participants gave signed informed consent;
no financial compensation was provided. This report followed the Strengthening the Reporting of
Genetic Association Studies (STREGA) reporting guidelinewhenever possible (summary statistics were
used in most analyses, and individual participant data were not always available).
Outcomes Ascertainment andDefinitions
Weighted genetic risk scores (wGRSs) for Lp(a) levels were engineered using data from the studies of
Burgess et al16 andMack et al17 and are described in eMethods 2 in the Supplement. A recent analysis
suggested that the association between genetically determined Lp(a) levels and cardiovascular
outcomes could be heterogeneous across studies that have used different instruments and different
assays tomeasure Lp(a) levels.18 Participants were asked the current age of their parents or the age
at which their parents had died. We used the definition of Pilling et al19 (described in eMethods 1 in
the Supplement and eFigure 3 in the Supplement) to define high parental life span in participants of
the UKBiobank.We also used summary statistics from a genome-wide association study of Timmers
et al11 ( joint analysis of the UKBiobank and the LifeGen Consortium) and another one by Zenin et al20
(age at the end of the health span in the UK Biobank) to study the association between LPA variants
and parental life span. In the combined analysis of the UK Biobank and LifeGen Consortium (26
additional population cohorts), the genetic architecture of human longevity was studied using more
than 1 million parental life spans with Cox proportional hazards regression models, as previously
described.11 To identify genetic loci associated with human health span, Zenin et al20 performed a
genome-wide association study on disease-free survival (age at the first occurrence of a major
chronic disease, including cancer, diabetes, congestive heart failure, myocardial infarction, chronic
obstructive pulmonary disease, stroke, dementia, or death) using the Cox-Gompertz proportional
hazards regressionmodel.
In EPIC-Norfolk, all individuals were flagged for mortality at the UK Office of National Statistics,
with vital status ascertained for the entire cohort. Death certificates for all decedents were coded
by trained nosologists according to the International Classification of Diseases, Ninth Revision. In
addition, participants admitted to the hospital were identified by their unique National Health
Service number by data linkage with the East Norfolk Health Authority database, which identifies all
hospital contacts throughout England andWales for Norfolk residents. In EPIC-Norfolk among 18 720
individuals with Lp(a) measurement, 5686 died (2412 of CVD) during the follow-up. Additional
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details on genotyping and selection of genetic instruments are described in eMethods 2 in the
Supplement.
Statistical Analysis
To evaluate the association between genetically determined Lp(a) levels and parental life span in the
UK Biobank, we performed 2-sample MR, in which the association between the selected single-
nucleotide polymorphisms (SNPs) and Lp(a) levels were obtained from Burgess et al16 and the
association of the SNPs with parental life span was assessed in the UK Biobank. First, we separated
individuals in the UK Biobank into quartiles based on wGRS distribution and performed logistic
regression, adjusting for age, sex, and the first 10 ancestry-based principal components to document
the association between genetically elevated Lp(a) levels and parental life span. Second, we obtained
effect estimates (adjusted for theminor allele frequency of each variant) by a 50-mg/dL increase in
Lp(a) levels, a threshold recently reported by Langsted et al.8 We used inverse-variance-weighted
MR (IVW-MR) and performed ameta-analysis of eachWald ratio (the effect of the genetic instrument
on Lp[a] levels divided by its effect on parental life span). To determine the significance of the
associations, a bootstrapmethod was used. A 2-tailed P value was calculated using a z test from
100000 random simulations. The IVW-MR is considered one of the simplest ways to obtain MR
estimates using multiple SNPs. The limitation of IVW-MR is the assumption that SNPs do not have
pleiotropic effects (effects on variables other than the trait of interest). To determine the presence of
unmeasured pleiotropy, we performed Egger-MR in which a nonzero y intercept is allowed to assess
violation of IVW-MR as described by Bowden et al.21 These analyses were performed using R, version
3.5.1 (R Foundation). In the IVW-MR analyses, all P values <.0083 (0.05/6 outcomes) were
considered as statistically significant.
In EPIC-Norfolk, Cox proportional hazards regressionmodels were used to calculate hazard
ratios (HRs) and corresponding 95% CIs for the risk of all-cause and cardiovascular mortality
associated with various thresholds of measured Lp(a) levels and 2 SNPs associated with high Lp(a)
levels. Hazard ratios for all-cause and cardiovascular mortality were obtained before and after
adjusting for cardiovascular risk factors (age, sex, smoking, bodymass index, systolic blood pressure,
diabetes, and creatinine level when evaluating measured Lp[a] levels and age and sex when
evaluating Lp[a]-increasing SNPs). We estimated the difference in survival between those with high
(95th percentile) vs low (<50th percentile) Lp(a) levels in age-equivalent terms by dividing the β
coefficient for all-cause mortality associated with high vs low Lp(a) levels by the β coefficient
difference in all-cause mortality associated with 1-year increases in age, as previously described.22,23
In EPIC-Norfolk, we also investigated the association between 2 SNPswith a strong associationwith
Lp(a) levels (rs10455872 and rs3798220) and all-cause and cardiovascular mortality. These analyses
were performed using SPSS software, version 12.0.1 (IBM SPSS). In the prospective analyses, all
2-tailed P values <.05 were considered as statistically significant.
Results
Of the 139 362 UK Biobank participants included in this analysis (mean [SD] age, 62.8 [3.9] years;
52%women), 17 686were considered as having high parental life span (at least 1 long-lived parent;
father still alive and age >90 y or father’s age at death90 y, or mother still alive and >93 y or
mother’s age of death93 y), and 2932 individuals were defined as having 1 parent with exceptional
longevity (top 1% survival). The definition of parental life span phenotypes is described in eMethods
1 in the Supplement. In the sex-specific analyses investigating paternal and maternal survival, 8976
individuals were considered as having high paternal life span and 10 137 were considered as having
highmaternal life span. Regardless of how longevity was defined and across all wGRSs used toweight
Lp(a) levels, genetically determined Lp(a) (whether examined as quartiles of the wGRS or as
continuous GRS) was negatively associatedwith a high parental life span in the UK Biobank. The odds
ratios for a high parental life span in the UK Biobank study population separated into quartiles of the
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Lp(a) wGRS are presented in Figure 1A and eFigure 4 in the Supplement (HR, 0.91; 95% CI,
0.87-0.96). Genetically determined Lp(a) levels were negatively associated with parental life span
and paternal andmaternal life span separately. The association per 50-mg/dL increase in Lp(a) (odds
ratio, 0.92; 95% CI, 0.89-0.94; P = 2.7 × 10−8) is presented in Figure 1B and eFigure 4 in the
Supplement (HR, 0.92; 95% CI, 0.89-0.94). Figure 1C and eFigure 4 in the Supplement present the
negative association between genetically determined Lp(a) levels and parental life span in themeta-
analysis of the UKBiobank and LifeGen Consortium and at the end of health span in the UKBiobank.
Figure 2 presents the association between the 26 LPA SNPs with Lp(a) levels and high parental
life span in the UKBiobank (Figure 2A), themeta-analysis of the UKBiobank and LifeGen Consortium
(Figure 2B), and the age at the end of the health span (Figure 2C). We obtained estimates of causal
effects of Lp(a) levels on parental life span in the UK Biobank using IVW-MR and Egger-MR (mean
[SD] Egger-MR slope, −0.0019 [0.0002]; P = 2.22 × 10−18) and health span (−0.0019 [0.0003];
P = 3.00 × 10−13). Egger-MR analysis revealed no evidence of horizontal pleiotropy in the 2 outcomes
that combined paternal andmaternal life span (Table 1). Therewas, however, evidence of horizontal
pleiotropy whenmaternal life span only was investigated (P value of intercept = .04). There was also
no evidence of horizontal pleiotropy in the association between LPA SNPs and parental life span in
the meta-analysis of the UK Biobank and the age at the end of the health span. Results presented in
Figure 1 and Figure 2 were obtained using a wGRS, with genetic instruments and weights obtained
from the study of Burgess et al.16 eFigures 4 and 5 in the Supplement present a technical replication
of these findings using genetic instruments and weights on Lp(a) and Lp(a)-adjusted for
apolipoprotein(a) isoform size obtained from the study of Mack et al.17 The association of each SNP
Figure 1. Association Between the Lp(a) Genetic Instruments, Parental Life Span, and Health Span
P Value
Favors Shorter
Parental
Life Span
Favors Longer
Parental
Life Span
1.110.85 0.90 0.95 1.05
OR (95% CI)
1.110.85 0.90 0.95 1.05
OR (95% CI)
1.110.85 0.90 0.95 1.05
OR (95% CI)
Cases/Controls,
No.Lp(a) Quartile
OR
(95% CI)
NA4489/30 352Q1 1.00 (1.00-1.00)
.214602/30 238Q2 1.03 (0.98-1.08)
.624444/30 396Q3 0.99 (0.95-1.03)
<.0014151/30 690Q4 0.91 (0.87-0.96)
Lp(a) quartiles and parental life span (UKB)A
P Value
Favors Shorter
Parental
Life Span
Favors Longer
Parental
Life Span
Cases/Controls,
No.Outcome
Effect per 50-mg/dL
Increase in Lp(a)
<.00117 686/121 676High parental life span 0.92 (0.89-0.94)
.0032932/121 676Top 1% parental life span 0.90 (0.83-0.96)
<.0018976/121 676High paternal life span 0.89 (0.86-0.93)
<.00110 137/121 676High maternal life span 0.93 (0.89-0.97)
Lp(a) quartiles and parental life span (UKB)B
P Value
Favors Shorter
Parental
Life Span
or Health Span
Favors Longer
Parental
Life Span
or Health SpanMethodOutcome
Effect per 50-mg/dL
Increase in Lp(a)
<.001IVWParental life span (UKB and LifeGen) 0.91 (0.89-0.92)
<.001EggerParental life span (UKB and LifeGen) 0.91 (0.89-0.93)
<.001IVWHealth span (UKB) 0.92 (0.90-0.94)
<.001EggerHealth span (UKB) 0.91 (0.88-0.93)
Lp(a) increases, parental life span (UKB and LifeGen), and health span (UKB)C
A, High parental life span in participants of the UK
Biobank (UKB) separated into quartiles of the Lp(a)
weighted genetic risk score (wGRS) from Burgess
et al.16 B, High parental life span, top 1% parental life
span, high paternal life span, and high maternal life
span associated with a 50-mg/dL increase in the LPA
wGRS in the UK Biobank from Burgess et al.16 C,
Parental life span and age at the end of the health span.
Models were adjusted for age, sex, and the 10 first
ancestry-based principal components. IVW indicates
inverse-variance weighted; Lp(a), lipoprotein(a); NA,
not applicable; OR, odds ratio; and Q, quartile. Error
bars indicate 95% CIs.
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from the study of Burgess et al16 andMack et al17 with these same outcomes are presented in
eFigures 6, 7, and 8 and in eTables 2, 3, and 4 in the Supplement.
The baseline characteristics of the EPIC-Norfolk study participants by Lp(a) levels are presented
in eTable 1 in the Supplement. Participants in the EPIC-Norfolk study were followed up for a mean of
20 years. Compared with participants with Lp(a) levels lower than 50mg/dL, those with Lp(a) levels
50mg/dL or higher had an increased HR of both all-cause and cardiovascular mortality (all-cause:
HR, 1.17; 95% CI, 1.08-1.27; cardiovascular: HR, 1.54; 95% CI, 1.37-1.72) (Table 2). In sex-specific
analyses, the association of high Lp(a) levels with cardiovascular mortality was observed in bothmen
and women, while the association of high Lp(a) levels with all-cause mortality was statistically
Figure 2. Mendelian Randomization Analysis of the Association Between Lipoprotein(a) (Lp[a]) and Longevity Phenotypes
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their association with Lp(a) levels from the study of Burgess et al16 and higher parental
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association of a single genetic variant with Lp(a) levels and a high parental life span. The
blue line represents the regression slope using the inverse-variance–weighted (IVW)
method and the orange line represents the regression slope using the Egger method.
Dashed lines indicate 95% CIs. MR indicates mendelian randomization; OR, odds ratio.
Error bars indicate 95% CI.
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significant only in men. No associations were found with the risk of noncardiovascular mortality in
the entire group and in the sex-specific analyses (eFigure 10 in the Supplement).
Table 3 presents the association of Lp(a) with all-cause and cardiovascular mortality in
participants above the 50th percentile of the Lp(a) level distribution. The risks for all-cause and
cardiovascular mortality were highest in participants with Lp(a) levels equal to or above the 95th
percentile (all-cause: HR, 1.17; 95% CI, 1.08-1.25; cardiovascular: HR, 1.54; 95% CI, 1.37-1.72). The
association between Lp(a) levels andmortality causes by baseline age are presented in eFigure 9 in
the Supplement. From the Cox proportional hazards regression model, the β coefficient (SE) for
all-cause mortality associated with each year increase in chronologic age was 0.127 (0.003). The β
coefficient (SE) for a comparison between high (95th percentile) vs low Lp(a) (<50th percentile)
Table 1. Estimates of the Association Between Lipoprotein(a) Levels and Parental Life Span in the UKB and LifeGen Consortium
Outcome IVW-MR, Slope Estimate (SD) P Value Egger-MR, Slope Estimate (SD) P Value Intercept P Valuea
High parental life span (UKB) −0.0020 (0.0004) 3.17 × 10−9 −0.0026 (0.0004) 1.68 × 10−8 0.0038 .08
Top 1% parental life span (UKB) −0.0027 (0.0008) 1.97 × 10−5 −0.0020 (0.0011) .06 −0.0048 −.35
High paternal life span (UKB) −0.0027 (0.0005) 1.43 × 10−8 −0.0028 (0.0005) 1.18 × 10−5 0.0006 .85
High maternal life span (UKB) −0.0017 (0.0004) 1.60 × 10−4 −0.0025 (0.0006) 4.00 × 10−5 0.0056 .04
Parental life span (UKB and LifeGen) −0.0020 (0.0002) 1.80 × 10−32 −0.0019 (0.0002) 2.22 × 10−18 −0.0007 .86
Health span (UKB) −0.0016 (0.0002) 3.21 × 10−16 −0.0019 (0.0003) 3.00 × 10−13 0.0084 .09
Abbreviations: IVW, inverse-variance weighted; MR, mendelian randomization; UKB,
UK Biobank.
a A P < .05 indicates that the y-intercept of theMR regression line is significantly
different from 0, suggesting unbalanced pleiotropy.
Table 2. Health Hazards AssociatedWith Elevated Lipoprotein(a) Levels
Outcomea
All Participants Men Women
<50 mg/dL ≥50 mg/dL <50 mg/dL ≥50 mg/dL <50 mg/dL ≥50 mg/dL
All-cause mortality
Cases/controls, event rate, No./No. (%) 4945/16 594 (29.8) 741/2126 (34.9) 2678/7504 (35.7) 359/879 (40.8) 2267/9090 (24.9) 382/1247 (30.6)
Model 1, HR (95% CI) 1 [Reference] 1.17 (1.08-1.27) 1 [Reference] 1.26 (1.13-1.40) 1 [Reference] 1.10 (0.99-1.23)
Model 2, HR (95% CI) 1 [Reference] 1.17 (1.08-1.27) 1 [Reference] 1.26 (1.13-1.41) 1 [Reference] 1.09 (0.98-1.22)
Cardiovascular mortality
Cases/controls, event rate, No./No. (%) 2026/16 594 (12.2) 386/2126 (18.2) 1170/7504 (15.6) 208/879 (23.7) 856/9090 (9.4) 178/1247 (14.3)
Model 1, HR (95% CI) 1 [Reference] 1.52 (1.36-1.70) 1 [Reference] 1.70 (1.47-1.97) 1 [Reference] 1.33 (1.13-1.57)
Model 2, HR (95% CI) 1 [Reference] 1.54 (1.37-1.72) 1 [Reference] 1.77 (1.52-2.05) 1 [Reference] 1.32 (1.11-1.55)
Abbreviation: HR, hazard ratio.
a Model 1 was adjusted for age and sex. Model 2was adjusted for age, sex, smoking, body
mass index, systolic blood pressure, diabetes, and estimated glomerular filtration rate.
Table 3. Health Hazards AssociatedWith Very High Lipoprotein(a) Levels
Outcomea
Lipoprotein(a) Percentiles
<50 50-80 81-90 91-95 >95-100
Lipoprotein(a) range, mg/dL <11.4 11.4 to <35.0 35.0 to <53.3 53.3 to <69.7 ≥69.7
All-cause mortality
Cases/controls, event rate (%) 2710/9365 (28.9) 1742/5614 (31.0) 568/1869 (30.4) 315/937 (33.6) 351/935 (37.5)
Model 1, HR (95% CI) 1 [Reference] 0.95 (0.89-1.01) 1.03 (0.94-1.13) 1.13 (1.00-1.27) 1.23 (1.10-1.38)
Model 2, HR (95% CI) 1 [Reference] 0.94 (0.89-1.00) 1.06 (0.97-1.16) 1.13 (1.00-1.27) 1.22 (1.09-1.37)
Cardiovascular mortality
Cases/controls, event rate (%) 1062/9365 (11.3) 738/5614 (13.1) 260/1869 (13.9) 165/937 (17.6) 187/935 (20.0)
Model 1, HR (95% CI) 1 [Reference] 1.01 (0.92-1.11) 1.21 (1.06-1.38) 1.54 (1.30-1.81) 1.70 (1.45-1.98)
Model 2, HR (95% CI) 1 [Reference] 1.00 (0.91-1.10) 1.26 (1.10-1.44) 1.52 (1.29-1.80) 1.71 (1.46-2.00)
Abbreviation: HR, hazard ratio.
a Model 1 was adjusted for age and sex. Model 2was adjusted for age, sex, smoking, body
mass index, systolic blood pressure, diabetes, and estimated glomerular filtration rate.
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levels was 0.194 (0.064), which is equivalent to approximately 1.5 years in chronologic age for
all-cause mortality risk. This analysis suggests that themortality risk for individuals with Lp(a) levels
equal to or above the 95th percentile is equivalent to being 1.5 years older in chronologic age.
For rs10455872, compared with noncarriers (AA genotype; event rate of 29.6% for all-cause
mortality and 12.2% for cardiovascular mortality), those who carried at least 1 Lp(a)-raising allele (AG
or GG genotype) were at higher risk for all-cause (HR, 1.14; 95% CI, 1.07-1.22; event rate, 31.9%) and
cardiovascular (HR, 1.23; 95% CI, 1.11-1.36; event rate, 13.9%) mortality. For rs3798220, compared
with noncarriers (TT genotype; event rate, 29.9% for all-causemortality and 12.4% for cardiovascular
mortality), thosewho carried at least 1 Lp(a)-raising allele (TC or CC genotype) were, however, not at
significantly higher risk for all-cause (HR, 1.03; 95% CI, 0.90-1.18; event rate, 29.3%) and
cardiovascular (HR, 1.16; 95% CI, 0.94-1.42; event rate, 13.4%)mortality. Compared with individuals
without an Lp(a)-raising allele, those with only 1 Lp(a)-raising allele (in rs10455872 or rs3798220)
had an increased risk of both all-cause and cardiovascular mortality (eFigure 11 in the Supplement).
Those with 2 or more Lp(a)-raising alleles had an even higher risk of all-cause and cardiovascular
mortality, although the association with cardiovascular mortality did not reach statistical significance
(HR, 1.40; 95% CI, 0.98-2.00). However, there were only 202 individuals in that subcategory,
including 30who died of CVD. No associations were found with the risk of noncardiovascular
mortality.
Discussion
Results of our MR study suggest that genetically determined Lp(a) levels are associated with parental
life span and age at the end of the health span.We also provide evidence that genetically determined,
aswell as absolute Lp(a) levels, are associatedwith the long-term risk of all-cause and cardiovascular
mortality in 18 720 participants of the EPIC-Norfolk prospective population study followed up for a
mean of 20 years, in which the mortality risk for those with Lp(a) levels equal to or above the 95th
percentile were equivalent to being 1.5 years older in chronologic age. Altogether, our results suggest
that variants at LPA, through an increase in absolute Lp(a) levels, may be important determinants of
human longevity.
Because the association between Lp(a) and longevity phenotypes is mostly related to its
association with CVDmortality, one can speculate that Lp(a) may be a cause of premature mortality
rather than the absence of Lp(a) being a cause of extreme longevity. Many pathobiological
mechanisms have been proposed to explain the detrimental association of Lp(a) and health
outcomes. First, Lp(a) is an important carrier of oxidized phospholipids in the bloodstream.24
Oxidized phospholipids are proinflammatory; they promote macrophage chemotaxis and oxidized
phospholipid uptake within the arterial wall, where they also promote tissue necrosis.25,26 In
addition, oxidized phospholipids have procalcifying properties. LPA is the top genetic loci for aortic
stenosis, and studies have shown that Lp(a) was linkedwith aortic valvemicrocalcification in patients
with and without aortic stenosis.3,27
In a 2017 genetic association study that sought to identify variants related to parental life span,
Joshi et al12 identified 4 loci, including the LPA locus, to be associated with parental life span at the
genome-wide significance level. In a follow-up study of more than 1 million parental life spans,
Timmers et al11 confirmed the association between variants in LPA and parental life span. Interesting
results were also recently reported by Zenin et al,20 who have suggested that variants in LPAmay
be associated with disease-free survival (also known as health span) in the UK Biobank, thereby
suggesting that lower Lp(a) levels might not only be associated with longer life span but also with
healthy living into old age. These studies, however, did not investigate the potential association of
genetically elevated Lp(a) levels and parental life span or health span using robust genetic analyses,
such as MR. By reporting a significant association of high Lp(a) levels with shorter parental life span
and lower age at the end of the health span using MR in the 2 aforementioned studies, our study
strengthens the possibility that Lp(a) is a potential causal determinant of human longevity.
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Results of our study also provide support for the use of parental life span for the study of the
genetic determinants of human longevity. The association between our trait of interest and parental
life span reported herein using a 2-sample MR study design and subsequent validation in a long-
term, prospective study that included 18 720 apparently healthy individuals with 5686 incident
mortality cases also support the use of MR as a tool or surrogate to study the genetic makeup of
human longevity. Mendelian randomization studies could be useful to determine whether suspected
biological determinants of longevity have a potentially causal role in the genesis of this complex trait.
In 2009, the Emerging Risk Factor Collaboration reported a positive association between high
Lp(a) levels and cardiovascular, but not all-cause, mortality in a meta-analysis of 24 long-term,
prospective studies.5 More recently, investigators of 2 Danish prospective population studies
(Copenhagen City Heart Study and Copenhagen General Population Study) also suggested a possible
association between high levels of Lp(a) and all-cause and cardiovascular mortality in the general
population.8 In these Danish studies, compared with participants in the bottom 50th percentile of
the Lp(a) level distribution (all-cause mortality event rate of 14.2% and cardiovascular mortality
event rate of 3.6%), participants with Lp(a) levels above the 95th percentile had an HR for all-cause
mortality of 1.20 (95% CI, 1.10-1.30; event rate, 16.5%) and an HR for cardiovascular mortality of 1.50
(95% CI, 1.28-1.76; event rate, 5.0%). In our study using comparable subgroups, we found that the
HRs for all-cause and cardiovascular mortality were consistent with the Danish studies. In our study,
however, the absolute risk of all-cause and cardiovascular mortality in participants with Lp(a) levels
above the 95th percentile was 8.6% higher for all-causemortality and 8.7% higher for cardiovascular
mortality than the group with low Lp(a) levels. The absolute risk associated with high Lp(a) levels
reported herein is considerably higher than what was observed in the Copenhagen City Heart Study
and Copenhagen General Population Study (2.5% for all-cause mortality and 1.4% for cardiovascular
mortality). However, in contrast with the Copenhagen City Heart Study and Copenhagen General
Population Study reports of a null association between the Lp(a)-raising variant rs10455872 and
all-cause and cardiovascular mortality, we found a strong dose-response association between the
number of rs10455872-G alleles and all-cause and cardiovascular mortality, thereby suggesting that
absolute Lp(a) levels are associated with all-cause and cardiovascular mortality.
Limitations
Limitations of our study include the use of individuals of European ancestry only. Confirmation of our
findings that the high Lp(a) levels may influencemortality risk in other ethnic groups from different
regions of the world will be needed to optimally plan randomized clinical trials of Lp(a) inhibition. We
also only included patients from a primary prevention setting in EPIC-Norfolk. This study sample is
not optimal to inform a randomized clinical trial design, which will likely be conducted in secondary
prevention settings.
Conclusions
Only a long-term clinical trial of Lp(a)-level lowering with investigative therapies will inform on the
clinical benefits of change in risk or health trajectories of individuals with high Lp(a) levels. Under the
assumption of a potential causal association between elevated Lp(a) levels and human longevity, our
results provide support for the early identification and long-term treatment of individuals with
elevated Lp(a) levels to promote life span as well as healthy living into old age.
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